Alivus Life Sciences Limited (NSE: ALIVUS) announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for INR 91.2 million. This strategic move aims to leverage IQGenX’s expertise in advanced formulation development, enhancing Alivus’s capabilities in oral solids, sterile injectables, and ophthalmic solutions. The acquisition will enable Alivus to expand its global customer base in the generic pharmaceutical segment.

Enhanced Formulation Development

IQGenX, founded in 2016, specializes in formulation development for highly regulated markets. This acquisition will allow Alivus to integrate end-to-end platforms offering deep scientific expertise across complex delivery formats. Alivus will now provide rigorous bioequivalence and stability studies, enabling comprehensive regulatory filings for diverse global markets.

Expanded Service Platform

The expanded service platform will cover pre-formulation studies, prototype development, process optimization, clinical supplies, and full-scale commercial manufacturing. Additionally, analytical development, methods validation, stability programs, and complete regulatory submission support will be offered. This will significantly scale up Alivus’s value proposition for global CDMO customers.

Alivus will strategically leverage IQGenX’s specialized platform alongside its own world-class API portfolio, focusing on oncology to curate a high-impact basket of differentiated, niche assets. These assets, backed by validated commercial-scale manufacturing capabilities, are primed for strategic out-licensing across multiple geographies.

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Alivus Life Sciences Limited

Alivus Life Sciences Limited belongs to the Healthcare › Drug Manufacturers – Specialty & Generic sector. Here’s a quick read on where the business and the stock stand today.

Alivus gains 32.8% over three months and trades near its 52-week highs. The PEG stands at 4.35 — severely stretched. Any earnings miss could trigger a sharp de-rating. Margins at 23.3% are impressive but need to be sustained — any compression would be a red flag. RSI hits 74, a level that signals the stock runs hot. Notably, buyers drove volume on 15 recent sessions — though at these levels, some profit-taking is normal. The stock rises 32.8% in three months on 7.6% revenue growth. As a result, the market gives it more credit than the fundamentals strictly justify. Watch the next quarterly results. If growth accelerates, the move makes sense. If not, expect some gains to unwind. Check Fundamentals of Alivus Life Sciences Limited.

Alivus Life Sciences Limited (ALIVUS) breaks out, gaining +10% to ₹1342.9 on the NSE on 04 Aug 2026. This move is driven by the stock clearing its 6M resistance trendline, transitioning from a breakdown to a breakout. Alivus operates in the specialty and generic drug manufacturing segment within the healthcare sector. Today’s move appears to be company-specific, driven by technical factors rather than broader sector momentum.

Technical setup — trendlines & DMA

Currently, Alivus is trading above its 6M support trendline at ₹1176.5, which is 12.39% below today’s price, and has broken through its 6M resistance trendline at ₹1205.83, now 10.21% above it. The stock is also 10.49% above its 50-DMA at ₹1099.1 and 23.23% above its 200-DMA at ₹985.5, indicating a stretched move. Within its 52W range of ₹819.0–₹1225.0, the stock is in the upper third, suggesting that much of the recent momentum is already priced in.

Fundamentals & business context

With a PE of 24.7 and profit margins at 23.3%, Alivus’s valuation appears to be reflecting its solid earnings quality. However, the revenue CAGR of 7.6% and profit CAGR of 6.5% over the past five years suggest that the stock’s price may be somewhat stretched relative to its growth rate. The 8.9% institutional ownership indicates a cautious approach by smart money, possibly due to the stock’s overvalued PEG ratio of 3.80. There is no NSE catalyst today, making this move primarily technical.

Algorithmic scorecard

The overall algorithmic scorecard indicates a technically strong but fundamentally weaker profile. The strongest signals are the bullish trend, with the 50-DMA above the 200-DMA, and the bullish sentiment over the last 30 days, where volume on up days has been 1.31x higher than on down days. These signals suggest systematic accumulation and positive momentum. However, the weakest signals are the overvalued PEG ratio and the negligible dividend yield, which represent risks of overpricing and lack of income generation, respectively.

Company outlook

Management outlined several key forward-looking metrics and strategic initiatives. They expect to sustain EBITDA margins between 30% to 32% going forward and plan a capex of about INR 540 crores for FY27, funded through internal accruals. Capacity utilization in brownfield is expected to reach 80-90% in 2 to 3 quarters, while Solapur is projected to start with 40-50% utilization, increasing to 60-70% the following year. The CDMO business is expected to see continued momentum with new deals on the horizon. A significant revenue jump is anticipated in FY28 as capex comes online. Strategic priorities have shifted towards lateral growth and higher entry barriers to sustain profitability, with an even distribution of revenue across mature geographies and a growing presence in Japan. Capacity expansion is planned from 1,198 KL in FY24 to 2,690 KL by FY28, and R&D spend is expected to settle around 4% of sales in the next 2 to 3 years. The company also hopes to close 2 new CDMO deals in the early second half of the current year.

Get all details on ALIVUS — P&L, peers, shareholding and more on TradeAlone.

Alivus Life Sciences Limited (ALIVUS) bounced intraday by +5% to ₹1151.9, recovering despite a weak 6M trendline structure that remains in breakdown. The move was backed by the company’s Q1 FY27 results, where it reported a 32% YoY increase in PAT and margins at 25%. Alivus operates in the specialty and generic drug manufacturing segment, and today’s bounce appears to be company-specific rather than a sector-wide momentum shift.

Technical setup — trendlines & DMA

The current 6M trendline structure shows a breakdown, with the stock trading below both the support and resistance trendlines. The 6M support trendline is at ₹1214.56, which is 5.44% above today’s price, while the resistance trendline is at ₹1205.83, 4.68% above today’s price. The 50-DMA at ₹1094.8 is slightly above today’s price, indicating a key momentum test. The stock is currently trading above both the 50-DMA and the 200-DMA at ₹982.5, suggesting a bullish trend but with limited upside momentum. In the 52W range of ₹819.0–₹1193.9, the stock is in the upper third, indicating that much of the potential upside may already be priced in.

Fundamentals & business context

With a PE of 23.9 and profit margins at 22.1%, Alivus Life Sciences appears to be valued at a premium relative to its current earnings growth. The revenue CAGR of 7.6% and profit CAGR of 6.5% over the past 5 years suggest moderate growth, which may not fully justify the current valuation. The 8.9% institutional ownership indicates a cautious approach by smart money, possibly reflecting concerns over the company’s valuation relative to its growth metrics. Today’s move was directly influenced by the Q1 FY27 results, which showed strong financial performance.

Algorithmic scorecard

The overall algorithmic scorecard of 68 reflects a balanced but slightly weak technical and fundamental picture. The strongest signals include the company’s excellent efficiency with a 22.1% profit margin and very low debt with a D/E ratio of 0.00, indicating strong financial health. Additionally, the bullish trend signaled by the 50-DMA being above the 200-DMA and the stock’s position above both moving averages suggest positive momentum. However, the weakest signals are the overvalued PEG of 3.68, which suggests the stock is expensive relative to its growth rate, and the negligible dividend yield of 0.45%, offering little income to investors. These factors present risks that could impact the stock’s performance in the near term.

Company outlook

Management provided forward guidance indicating confidence in sustaining EBITDA margins in the range of 30% to 32% going forward. Capex of about INR 540 crores is planned for FY27, funded through internal accruals, with capacity utilization in brownfield expected to reach 80-90% in 2 to 3 quarters. The Solapur facility is expected to start with 40-50% utilization and reach 60-70% in the following year. The CDMO business is expected to continue gaining momentum with revival in earlier projects and new deals. Significant revenue growth is anticipated in FY28 due to capex coming live. Capacity expansions in Solapur and Ankleshwar are planned to support future growth, with R&D spend expected to settle around 4% of sales in the next 2 to 3 years. The company aims to close 2 new CDMO deals in the early second half of the current year.

Get all details on ALIVUS — P&L, peers, shareholding and more on TradeAlone.